News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 14, 2025

Key Benefits of CGM Technology

Author(s)Davida Kruger, MSN, APN-BC, BC-ADM , Jaime Murillo, MD, FACC, FASE , Ian Neeland, MD, FAHA, FACC

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss the key benefits of continuous glucose monitoring (CGM) technology compared with traditional monitoring based on recent clinical trial data, including research on cardiovascular risk reduction in noninsulin-treated T2D.

Episodes in this series

1 KOL is featured in this series.

EP. 1 CGM: Redefining Type 2 Diabetes Management

EP. 2 Key Benefits of CGM Technology

EP. 2 Key Benefits of CGM Technology

EP. 3 CGM's Impact on Clinical Inertia

EP. 3 CGM's Impact on Clinical Inertia

EP. 4 CGM vs Traditional Monitoring

EP. 4 CGM vs Traditional Monitoring

EP. 5 Understanding CGM Metrics

EP. 5 Understanding CGM Metrics

EP. 6 Health Care System Integration

EP. 6 Health Care System Integration

EP. 7 CGM Coverage and Access

EP. 7 CGM Coverage and Access

EP. 8 Implementation Barriers

EP. 8 Implementation Barriers

EP. 9 Overcoming Access Challenges

EP. 9 Overcoming Access Challenges

EP. 10 Adoption Strategies

EP. 10 Adoption Strategies

EP. 11 The Metro Nashville Public Schools Initiative

EP. 11 The Metro Nashville Public Schools Initiative

EP. 12 Health Care Quality Impact

EP. 12 Health Care Quality Impact

EP. 13 Population Outcomes and Return on Value With CGMs

EP. 13 Population Outcomes and Return on Value With CGMs

EP. 14 Long-Term Outcomes Assessment

EP. 14 Long-Term Outcomes Assessment

EP. 15 Closing Perspectives

EP. 15 Closing Perspectives

Video content above is prompted by the following:

Based on recent clinical trial data, including your research on cardiovascular-risk reduction in noninsulin patients, what are the key benefits of CGM technology compared with traditional monitoring?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Mark Belkin, MD

HFpEF Is Missed at Referral, But Not Untreatable: Mark Belkin, MD

ByPearl Steinzor

September 16th 2026

Dr Amandeep Godara | Image Credit: University of Utah

Personalizing Relapsed Multiple Myeloma Therapy: Amandeep Godara, MBBS

ByBrooke McCormick,Amandeep Godara, MBBS

September 16th 2026

EBO horizontal thumb | Image: AJMC

A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability

ByLucio N. Gordan, MD,R. Steven Paulson, MD,David T. Wenk, MD,Paul A. S. Fishkin, MD,David R. Drosick, MD,Tracy W. Dobbs, MD,Richard M. Ingram, MD, FASCO,Rupesh J. Parikh, MD,Michael A. Danso, MD,Brian J. Heller, MD,Manojkumar Bupathi, MD, MS,David Cosgrove, MD,Mark T. Fleming, MD

September 16th 2026

Dr Christos Vaklavas | Image Credit: University of Utah

Removing Barriers to Rural Oncology Care: Christos Vaklavas, MD

ByBrooke McCormick,Christos Vaklavas, MD

September 15th 2026

Doctor with female patient | Image credit: Liudmila Dutko - stock.adobe.com

FDA Shortens Tarlatamab Monitoring, Widens Access to SCLC Care

ByLaura Joszt, MA

September 14th 2026

Trending on AJMC

FDA Clears First Alzheimer Blood Test for Adults as Young as 40

5 Things to Know About the 2026 ESC Heart Failure Guidelines

A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability

Early Signs of Success for Missouri’s New Notification of Pregnancy

Dupilumab Eases Chronic Hand Eczema With or Without Atopic Background